Capecitabine in the treatment of esophageal and gastric cancers Review uri icon

Overview

MeSH Major

  • Antimetabolites, Antineoplastic
  • Deoxycytidine
  • Esophageal Neoplasms
  • Fluorouracil
  • Stomach Neoplasms

abstract

  • Improvements in understanding molecular mechanisms of disease, defining distinct disease subtypes based on histology, genetic background and levels of protein expression as well as signaling pathways may start to clarify the reasons underlying heterogeneous clinical behaviors and different outcomes between patients with seemingly similar tumor types. Capecitabine ushered in the era of oral chemotherapy, providing ease of administration with comparable if not superior efficacy to its older parental counterpart. The best way to fully exploit its potential in gastroesophageal cancers is being actively studied worldwide at all stages of disease management.

publication date

  • December 2013

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1517/13543784.2013.842974

PubMed ID

  • 24090307

Additional Document Info

start page

  • 1645

end page

  • 57

volume

  • 22

number

  • 12